Iterum Therapeutics PLC 8-K Filing

FAQ

Key Financial Figures

• $0.01 — registered Ordinary Shares, par value $0.01 per share ITRM The Nasdaq Stock Mar
• $1.00 — lure to maintain a minimum bid price of $1.00 per share for continued listing on The

Filing Documents

• itrm-20260330.htm (8-K) — 49KB
• 0001193125-26-133247.txt ( ) — 151KB
• itrm-20260330.xsd (EX-101.SCH) — 24KB
• itrm-20260330_htm.xml (XML) — 4KB

01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously reported, on February 24, 2026, Iterum Therapeutics plc (the "Company") received a delisting determination letter (the "Prior Determination Letter") from The Nasdaq Stock Market LLC ("Nasdaq") indicating that as a result of the Company's failure to maintain a minimum bid price of $1.00 per share for continued listing on The Nasdaq Capital Market, the Company's ordinary shares were scheduled for delisting and would be suspended from trading on Nasdaq (the "Prior Delisting Determination"). On March 3, 2026, the Company requested a hearing of the Prior Delisting Determination before an independent Nasdaq Hearings Panel (the "Panel"), which automatically stayed any suspension or delisting action pending the hearing. Also as previously disclosed, on March 27, 2026, the Company filed a petition in the High Court in Ireland to wind up the Company (the "Winding Up Petition"). In connection with the filing of the Winding Up Petition, the Company advised Nasdaq that it is withdrawing its appeal of the Prior Delisting Determination. Therefore, on March 30, 2026, the Company received a further letter from Nasdaq, notifying the Company that as a result of the Company withdrawing its appeal of the Prior Delisting Determination, the staff of Nasdaq has determined that the Company's ordinary shares will be delisted from Nasdaq. Trading of the Company's ordinary shares will be suspended at the opening of business on April 1, 2026, and a Form 25-NSE will be filed with the Securities and Exchange Commission (the "SEC"), which will remove the Company's ordinary shares from listing on Nasdaq.

01. Other Events

Item 8.01. Other Events. Given the Company's limited cash resources and the ongoing winding up process by Damien Murran and Jennifer McMahon of Teneo Restructuring (Ireland) Limited as the joint provisional liquidators, the Company does not expect to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 or make any other future filings with the Securities and Exchange Commission. Cautionary Note Regarding Forward-looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding the process and potential outcomes of the potential winding up of the Company and delisting of the Company's ordinary shares from Nasdaq and the Company's expectation that it will not continue to file reports with the SEC. In some cases, forward-looking statements can be identified by words such as "may," "believes," "intends," "seeks," "anticipates," "plans," "estimates," "expects," "should," "assumes," "continues," "could," "would," "will," "future," "potential" or the negative of these or similar terms and phrases. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include all matters that are not historical facts. Actual future results may be materially different from what is expected due to factors largely outside the Company's control, including risks and uncertainties concerning the approval by the Irish High Court of the Winding Up Petition; risks and uncertainties regarding the Company's ability to effect an orderly winding up of its business; the timing of delisting of the Company's ordinary shares from Nasdaq; any

SIGNATURES

SIGNATURES Authority and Capacity of Signatories The joint provisional liquidators are signing this report in their capacity as provisional liquidators of the Company only. Any personal liability is expressly excluded and their firm shall be under no liability affecting them personally or their estate. Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Iterum Therapeutics plc Date: March 31, 2026 By: /s/ Damien Murran Damien Murran Joint Provisional Liquidator For & on behalf of Iterum Therapeutics plc (In Provisional Liquidation)

View Full Filing

View this 8-K filing on SEC EDGAR